Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

Ivan O Rosas

Conclusions:In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days. (Funded by F.Hoffmann-La Roche and the Department of Health and Human Services; COVACTA ClinicalTrials.gov number,NCT04320615.).